D
Derek L. Stirewalt
Researcher at Fred Hutchinson Cancer Research Center
Publications - 112
Citations - 17324
Derek L. Stirewalt is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 42, co-authored 101 publications receiving 15718 citations. Previous affiliations of Derek L. Stirewalt include University of Washington Medical Center & University of Washington.
Papers
More filters
Journal ArticleDOI
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
Jason E. Farrar,Jenny L. Smith,Megan Othus,Benjamin J. Huang,Yi-Cheng Wang,Rhonda E. Ries,Tiffany A. Hylkema,Era L. Pogosova-Agadjanyan,Sneha Challa,Amanda R. Leonti,Timothy I. Shaw,Timothy J. Triche,Alan S. Gamis,Richard Aplenc,E. Anders Kolb,Xiaotu Ma,Derek L. Stirewalt,Todd A. Alonzo,Soheil Meshinchi +18 more
TL;DR: In this paper , the authors evaluated the annotated lncRNA landscape by transcript sequencing of 1,298 pediatric and 96 adult acute myeloid leukemia (AML) specimens and found that lncScores added to overall classification accuracy with at least comparable predictive performance to current stratification methods that rely on multiple assays.
Journal ArticleDOI
Requirement for N6-Methyladenosine mRNA Methylation during Human Erythropoiesis
Daniel A. Kuppers,Yong Peng,Sonali Arora,Cynthia L. Wladyka,Anna M. Wilhite,Derek L. Stirewalt,Beverly Torok-Storb,Andrew C. K. Hsieh,Chuan He,Patrick J. Paddison +9 more
TL;DR: In this article , the N6-methyladenosine (m6A) mRNA methyltransferase (MTase) complex was found to be required for human erythropoiesis in bone marrow-derived and G-CSF-mobilized CD34+ cells.
Patent
Methods and compositions for measuring radiation exposure in a subject
TL;DR: In this paper, a method for assessing exposure to ionizing radiation comprising the steps of (a) measuring the RNA expression level of certain biomarker genes in a biological sample; (b) correcting the RNA expressions of the measured biomarker in step (a), to a reference standard or threshold value, and (c) comparing the RNA expressed level of the biomarker measured in step(a) and corrected in accordance with step(b) to the corrected expression of a calibration sample or threshold values, wherein a difference in expression level between the biomarkers in the biological sample and the calibration
Journal ArticleDOI
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.
Christina M. Termini,Anna Moseley,Megan Othus,Frederick R. Appelbaum,Thomas R. Chauncey,Harry P. Erba,Ming Fang,Stanley Chun-Wei Lee,Jasmine Naru,Era L. Pogosova-Agadjanyan,Jerald P. Radich,Cheryl L. Willman,Feinan Wu,Soheil Meshinchi,Derek L. Stirewalt +14 more
TL;DR: In this paper , the authors propose a method to solve the problem of "not available" data: https://www.youtube.com/watch/watch?feature=youtu.
Journal ArticleDOI
Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition
Sayantani Sinha,Zhiyan Liu,Maxwell Bannister,Erica Arriaga-Gomez,Axia Song,Dawei Zong,Martina Sarchi,Elizabeth Bonner,Victor M. Corral,Cassandra Leibson,Wannasiri Chiraphapphaiboon,Derek L. Stirewalt,J. Deeg,Sumit Rai,Matthew J. Walter,Timothy A. Graubert,Sergei Doulatov,Dang Hai Nguyen,Stanley Chun-Wei Lee +18 more
TL;DR: In this paper , a focused drug screen using inhibitors targeting different DNA damage response pathways and drugs that inhibit DNA replication or DNA metabolic processes was performed to identify novel therapeutic targets in SF-mutant myeloid malignancies.